AQEMIA

AQEMIA is a next-gen pharmatech company with a mission to design fast innovative drug candidates for critical diseases, such as immuno-oncology. Utilizing quantum-inspired physics algorithms and generative AI, the company has rapidly generated one of the world's fastest-growing drug discovery pipeline, avoiding reliance on experimental data. With several successful drug discoveries in its internal pipeline and collaborations with pharmaceutical companies, AQEMIA now focuses on in vivo optimization. Founded in 2019, the company is headquartered in Paris and London. The recent $38.00M Series A investment on 10 December 2024 involved notable investors including Cathay Innovation, Elaia, Euazeo, Bpifrance Large Venture, and Wendel Growth. As the company continues to grow, it is actively hiring and offers insights into its operations through various platforms.